LONDON, April 14, 2014 /PRNewswire/ --
On Friday, April 11, 2014, the NASDAQ Composite ended at 3,999.73, down 1.34%, the Dow Jones Industrial Average declined 0.89% to 16,026.75, and the S&P 500 closed at 1,815.69, down 0.95%. The losses were broad based as all the 10 sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 644.74, down 1.07%, and the same has lost 4.46% in the last one month. Investor-Edge has initiated coverage on the following equities: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Incyte Corp. Ltd (NASDAQ: INCY), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) and Aastrom Biosciences Inc. (NASDAQ: ASTM). Free technical research on ALXN, INCY, MACK and ASTM can be downloaded upon signing up at:
Shares in Alexion Pharmaceuticals Inc. declined 3.18% on Friday, closing at $139.61, after oscillating between $138.73 and $147.50. A total of 2.47 million shares were traded, which is above its three months average volume of 1.90 million shares. Shares in Alexion Pharmaceuticals Inc. have lost 21.52% in the last one month, while the same has gained 3.25% in the previous three months and 5.06% on YTD basis. The company's stock is trading above its 200-day moving average. Alexion Pharmaceuticals Inc.'s 50-day moving average of $166.13 is above its 200-day moving average of $129.62. Furthermore, the company's stock is trading at a PE ratio of 97.81 and has a Relative Strength Index (RSI) of 35.74. Sign up today to read free research on ALXN at:
Incyte Corp. Ltd's stock witnessed a trading volume of 2.62 million shares on Friday, as compared with its three months average volume of 2.09 million shares. The stock ended the day at $46.25, down 1.87%, after trading between $46.10 and $49.52. Incyte Corp. Ltd's shares have declined 29.23% in the last one month and 8.65% on YTD basis. The stock is trading above its 200-day moving average. Incyte Corp. Ltd's 50-day moving average of $60.69 is above its 200-day moving average of $44.79. Additionally, the company's shares have an RSI of 31.39. Sign up today to read free research on INCY at:
On Friday, shares in Merrimack Pharmaceuticals Inc. fell by 3.27% finishing the session at $4.73. The stock recorded a trading volume of 1.07 million shares which is below its three months average volume of 1.50 million shares. The stock fluctuated between $4.69 and $4.95 during the session. Shares in Merrimack Pharmaceuticals Inc. have fallen by 15.69% in the last one month and 11.27% on YTD basis. The stock is trading above its 200-day moving average. Merrimack Pharmaceuticals Inc.'s 50-day moving average of $5.18 is above its 200-day moving average of $4.55. Moreover, the company's shares have an RSI of 38.81. Sign up today to read free research on MACK at:
Aastrom Biosciences Inc. shares recorded a trading volume of 0.35 million shares, as compared with its three months average volume of 0.38 million shares. The stock ended Friday's session at $3.63, down 6.68%, and at an intraday trading range of $3.60 and $3.83. Aastrom Biosciences Inc.'s shares have gone down by 9.70% in the last one month and 9.93% in the previous three months, while the same has surged 12.38% on YTD basis. The stock is trading below its 50-day and 200-day moving averages. Aastrom Biosciences Inc.'s 200-day moving average of $4.96 is above its 50-day moving average of $3.82. Further, the company's shares have an RSI of 43.27. Sign up today to read free research on ASTM at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Earnings Source